IRADIMED Reports Strong Q1 Growth, Reaffirms 2026 Guidance, and Sees Strong Demand for New Product

summarizeSummary

IRADIMED reported strong first-quarter financial results, including significant revenue and EPS growth, reaffirmed its full-year guidance, and announced strong early demand for its newly launched next-generation product.

check_boxKey Events

• Strong Q1 Financial Performance

  Reported Q1 2026 revenue of $22.0 million, a 13% increase year-over-year, and GAAP diluted EPS of $0.45, up 22% from the prior year. Non-GAAP diluted EPS was $0.49, a 17% increase.

• Reaffirmed Full-Year 2026 Guidance

  The company reaffirmed its full-year 2026 revenue guidance of $91.0 million to $96.0 million and GAAP diluted EPS guidance of $1.90 to $2.05, indicating confidence in continued growth.

• Successful Launch of Next-Generation Product

  Announced the commercial launch of its next-generation 3870 MRI-compatible IV infusion pump system, reporting tremendous interest and strong early order activity.

• Significant Increase in Cash Flow from Operations

  Cash flow from operations for Q1 2026 was $8.3 million, a 93% increase compared to $4.3 million in the same period of 2025.

auto_awesomeAnalysis

IRADIMED's first-quarter results demonstrate robust financial and operational performance, with significant growth in revenue and earnings per share. The reaffirmation of full-year guidance, following a strong Q1, signals management's confidence in sustained performance. The successful commercial launch of the next-generation 3870 MRI-compatible IV infusion pump system, coupled with strong early order activity, positions the company for accelerated growth in the latter half of the year. The substantial increase in cash flow from operations further strengthens the company's financial health.